Intrauterine Device – Levo­nor­gestrel 52 mg [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2021-07-02 17:18 (324 d 17:57 ago) – Posting: # 22454
Views: 658

Hi Marianna,

» We used data from the article: "Comparative pharmacokinetic analysis of levonorgestrel-releasing intrauterine systems and » levonorgestrel-containing contraceptives with oral or subdermal administration route" Hofmann et. al, 2020.
» But the point still the number of subjects in this BE/BA study, because in this case, parallel design needs an intra+inter CV%.

Actually you need CVtotal. That’s not the sum (or average) of both. You need to average the variances and back-convert them to a CV. In [image]:

pooling <- function(CV.inter, CV.intra) {
  CV2var <- function(CV)  return(log(CV^2 + 1))
  var2CV <- function(var) return(sqrt(exp(var) - 1))
  return(var2CV(mean(c(CV2var(CV.inter), CV2var(CV.intra)))))
CV.inter <- 0.80
CV.intra <- 0.40 <- pooling(CV.inter, CV.intra)
cat("CV.inter =", sprintf("%.2f%%", 100 * CV.inter),
    "\nCV.inter =", sprintf("%.2f%%", 100 * CV.intra),
    "\ =", sprintf("%.2f%%", 100 *, "\n")


CV.inter = 80.00%
CV.inter = 40.00% = 61.59%

» But in a scientific literature review, we don't find something like that.

I don’t have this article. If the study was performed in a parallel design, you have already CVtotal. If it was not reported, you can calculate it from the confidence interval and the sample size by the function CVfromCI() in PowerTOST. If it was a crossover (very, very unlikely), use the code above.

» A suggestion about mitigating the error in subject number determination?

Not sure what you mean by that. Perhaps this article helps.

Dif-tor heh smusma 🖖 [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
22,091 posts in 4,630 threads, 1,567 registered users;
online 13 (1 registered, 12 guests [including 4 identified bots]).
Forum time: Monday 11:16 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz